What precision oncology means in practice
Precision oncology uses information about a cancer’s molecular characteristics alongside pathology, disease context, and clinical history. Biomarkers may help clinicians interpret disease biology, understand evidence for targeted approaches, and determine which additional questions warrant investigation.
Our review scope
MPO supports treating oncologists and multidisciplinary cancer teams by organizing reported genomic findings, examining biomarker–treatment evidence, and identifying uncertainty or limitations in the data. Reviews are designed to complement—not replace—pathology assessment, molecular tumor boards, or clinician-led decisions.
What a focused review can address
A request may involve interpreting NGS findings, assessing the evidence behind a proposed targeted therapy, comparing biomarker-defined treatment literature, or identifying trial questions to discuss with the responsible clinical team.
Evidence in context
An alteration detected on a panel is not by itself a treatment recommendation. Cancer type, variant classification, treatment line, tissue context, regulatory status, and the quality of available studies matter. Our approach separates established clinical evidence from exploratory research.
Related scientific resource
Explore the independently developed OncoAtlas evidence maps for cancer-specific research context. The maps are informational resources and do not replace current guideline review.
Related resource: OncoAtlas cancer evidence maps. Published profile: OncoDaily feature.